Bone fragility in Type 2 Diabetes Mellitus. Influence of sex and cardiovascular disease in a pilot study using metabolomics
Type 2 diabetes mellitus (T2DM) is one of the most common worldwide metabolic disorders, characterized by insulin resistance (IR) and defective insulin secretion by pancreatic β-cells which leads to multiple complications such as bone fragility. This complication might be influenced by other factors...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Talanta Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266683192400095X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850245194482450432 |
|---|---|
| author | Nicolás Redecilla-Montoya Cristina García-Fontana Tomás Clive Barker-Tejeda Andrea Macías-Camero Francisco Andújar-Vera María Fernanda Rey-Stolle Luis Martínez-Heredia Iván Iglesias-Baena Ana Gradillas Coral Barbas Beatriz García-Fontana Manuel Muñoz-Torres Alma Villaseñor |
| author_facet | Nicolás Redecilla-Montoya Cristina García-Fontana Tomás Clive Barker-Tejeda Andrea Macías-Camero Francisco Andújar-Vera María Fernanda Rey-Stolle Luis Martínez-Heredia Iván Iglesias-Baena Ana Gradillas Coral Barbas Beatriz García-Fontana Manuel Muñoz-Torres Alma Villaseñor |
| author_sort | Nicolás Redecilla-Montoya |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is one of the most common worldwide metabolic disorders, characterized by insulin resistance (IR) and defective insulin secretion by pancreatic β-cells which leads to multiple complications such as bone fragility. This complication might be influenced by other factors such as gender and cardiovascular disease (CVD). However, it is unclear why a certain T2DM group develops bone fragility, and what the molecular mechanism is. Metabolomics is a powerful approach to the study of human metabolism, especially in complex diseases such as T2DM. Thus, this study aimed to identify significant metabolites associated with bone fragility in T2DM patients. To achieve this, 81 individuals were enrolled and classified as T2DM patients (D, n=28), T2DM with bone fragility (D-Frag, n=25), or age-matched non-diabetic subjects (ND, n=28) as the control group. Serum samples were collected and analyzed using liquid chromatography and gas chromatography, both coupled to mass spectrometry (LC-MS and GC-MS, respectively). Samples were compared within four different scenarios: 1) the classical comparison of D vs ND to corroborate previous studies; 2) D-Frag vs D to explore the metabolites mainly associated with bone fragility; 3) the same comparison using male data (MD-Frag vs MD) to study as a more homogeneous model of bone fragility as in women, bone fragility could be mainly associated with hormonal stage and pregnancy; and 4) MD-Frag-CVD vs MD-CVD to explore the influence of bone fragility in the male-based model with CVD considering that most of the T2DM patients suffer from CVD. After analysis of these scenarios, our results suggest that acylcarnitines and glycerophospholipids, among other metabolites, are involved in the development of bone fragility in T2DM. |
| format | Article |
| id | doaj-art-bdb3b11a3e1142eabbb3ca9e1a31a3fa |
| institution | OA Journals |
| issn | 2666-8319 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Talanta Open |
| spelling | doaj-art-bdb3b11a3e1142eabbb3ca9e1a31a3fa2025-08-20T01:59:31ZengElsevierTalanta Open2666-83192024-12-011010038110.1016/j.talo.2024.100381Bone fragility in Type 2 Diabetes Mellitus. Influence of sex and cardiovascular disease in a pilot study using metabolomicsNicolás Redecilla-Montoya0Cristina García-Fontana1Tomás Clive Barker-Tejeda2Andrea Macías-Camero3Francisco Andújar-Vera4María Fernanda Rey-Stolle5Luis Martínez-Heredia6Iván Iglesias-Baena7Ana Gradillas8Coral Barbas9Beatriz García-Fontana10Manuel Muñoz-Torres11Alma Villaseñor12Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain; Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, SpainInstituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospital Universitario Clínico San Cecilio, Granada, Spain; CIBER on Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Endocrinology and Nutrition Unit. Hospital Universitario Clínico San Cecilio de Granada, Granada, SpainCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain; Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, SpainCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain; Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, SpainBioinformatic Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Computer Science and Artificial Intelligence, University of Granada, Granada, Spain; Andalusian Research Institute in Data Science and Computational Intelligence (DaSCI Institute), Granada, SpainCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, SpainInstituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospital Universitario Clínico San Cecilio, Granada, Spain; CIBER on Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, SpainResearch Unit, GenActive Clinic & Research, 18193 Granada, SpainCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, SpainCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, SpainInstituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospital Universitario Clínico San Cecilio, Granada, Spain; CIBER on Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Endocrinology and Nutrition Unit. Hospital Universitario Clínico San Cecilio de Granada, Granada, Spain; Corresponding authors.Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospital Universitario Clínico San Cecilio, Granada, Spain; CIBER on Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Endocrinology and Nutrition Unit. Hospital Universitario Clínico San Cecilio de Granada, Granada, Spain; Department of Medicine. University of Granada, Granada, SpainCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain; Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain; Corresponding authors.Type 2 diabetes mellitus (T2DM) is one of the most common worldwide metabolic disorders, characterized by insulin resistance (IR) and defective insulin secretion by pancreatic β-cells which leads to multiple complications such as bone fragility. This complication might be influenced by other factors such as gender and cardiovascular disease (CVD). However, it is unclear why a certain T2DM group develops bone fragility, and what the molecular mechanism is. Metabolomics is a powerful approach to the study of human metabolism, especially in complex diseases such as T2DM. Thus, this study aimed to identify significant metabolites associated with bone fragility in T2DM patients. To achieve this, 81 individuals were enrolled and classified as T2DM patients (D, n=28), T2DM with bone fragility (D-Frag, n=25), or age-matched non-diabetic subjects (ND, n=28) as the control group. Serum samples were collected and analyzed using liquid chromatography and gas chromatography, both coupled to mass spectrometry (LC-MS and GC-MS, respectively). Samples were compared within four different scenarios: 1) the classical comparison of D vs ND to corroborate previous studies; 2) D-Frag vs D to explore the metabolites mainly associated with bone fragility; 3) the same comparison using male data (MD-Frag vs MD) to study as a more homogeneous model of bone fragility as in women, bone fragility could be mainly associated with hormonal stage and pregnancy; and 4) MD-Frag-CVD vs MD-CVD to explore the influence of bone fragility in the male-based model with CVD considering that most of the T2DM patients suffer from CVD. After analysis of these scenarios, our results suggest that acylcarnitines and glycerophospholipids, among other metabolites, are involved in the development of bone fragility in T2DM.http://www.sciencedirect.com/science/article/pii/S266683192400095XUntargeted metabolomicsDiabetesBone fragilityLC-MSGC-MS |
| spellingShingle | Nicolás Redecilla-Montoya Cristina García-Fontana Tomás Clive Barker-Tejeda Andrea Macías-Camero Francisco Andújar-Vera María Fernanda Rey-Stolle Luis Martínez-Heredia Iván Iglesias-Baena Ana Gradillas Coral Barbas Beatriz García-Fontana Manuel Muñoz-Torres Alma Villaseñor Bone fragility in Type 2 Diabetes Mellitus. Influence of sex and cardiovascular disease in a pilot study using metabolomics Talanta Open Untargeted metabolomics Diabetes Bone fragility LC-MS GC-MS |
| title | Bone fragility in Type 2 Diabetes Mellitus. Influence of sex and cardiovascular disease in a pilot study using metabolomics |
| title_full | Bone fragility in Type 2 Diabetes Mellitus. Influence of sex and cardiovascular disease in a pilot study using metabolomics |
| title_fullStr | Bone fragility in Type 2 Diabetes Mellitus. Influence of sex and cardiovascular disease in a pilot study using metabolomics |
| title_full_unstemmed | Bone fragility in Type 2 Diabetes Mellitus. Influence of sex and cardiovascular disease in a pilot study using metabolomics |
| title_short | Bone fragility in Type 2 Diabetes Mellitus. Influence of sex and cardiovascular disease in a pilot study using metabolomics |
| title_sort | bone fragility in type 2 diabetes mellitus influence of sex and cardiovascular disease in a pilot study using metabolomics |
| topic | Untargeted metabolomics Diabetes Bone fragility LC-MS GC-MS |
| url | http://www.sciencedirect.com/science/article/pii/S266683192400095X |
| work_keys_str_mv | AT nicolasredecillamontoya bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT cristinagarciafontana bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT tomasclivebarkertejeda bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT andreamaciascamero bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT franciscoandujarvera bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT mariafernandareystolle bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT luismartinezheredia bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT ivaniglesiasbaena bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT anagradillas bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT coralbarbas bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT beatrizgarciafontana bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT manuelmunoztorres bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics AT almavillasenor bonefragilityintype2diabetesmellitusinfluenceofsexandcardiovasculardiseaseinapilotstudyusingmetabolomics |